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1. Introduction 
The various effects that interferon exerts in 
exposed cells are supposed to be triggered by its inter- 
action with specific receptors in the cell membrane 
[ 1,2]. Measuring circulating interferon blood levels 
therefore has become a widely applied tool during 
systematically administered interferon therapy. Dem- 
onstration of interferon in tissues would provide 
more conclusive evidence that exogenous interferon 
indeed will reach the membranes of target cells. This 
question is of some clinical importance especially in 
cases when HIFN-fl is used, since this type of inter- 
feron is rapidly inactivated and circulating interferon 
blood levels can be detected but hardly after sub- 
cutaneous or intramuscular application of HIFN$ in 
both men and animals [3,4]. We describe here the 
presence of HIFN-fl in the liver tissue of 3 male 
patients with chronic active hepatitis B, who under- 
went HIFN-/3 treatment. HIFN-fl was shown attached 
to the walls of sinosoids by means of indirect immu- 
nofluorescence using a monoclonal anti-IFNP. 
2. Materials and methods 
The HIFN$ used was kindly provided by Dr 
Rentschler, Arzneimittel GmbH, Laupheim. The 
interferon preparation was intravenously adminis- 
tered in all 3 individuals for 6 months. The doses 
applied were 10 Mio U/day for 1 month and 10 Mio U 
every 3 days for 5 months. Liver biopsies were per- 
formed as in [5,6] at the last day of HIFN-fl treat- 
ment immediately after a 10 min infusion of 10 Mio U 
of HIFN-/.j’ [5,6]. The specimens were embedded in 
tissue Tek II@, (Lab Tek Prod., Miles, Naperville IL) 
and were frozen in liquid nitrogen promptly there- 
after. Subsequently unfixed 3.5 pm cryostat sections 
were prepared, rinsed with barbital buffer (pH 7.2) 
for I 5 min and incubated with a 1:50 dilution of a 
monoclonal mouse-anti-HIFN-0 at room temperature 
for 30 min. 
The monoclonal mouse anti-HIFN;O antibody was 
obtained from a stable FO-myeloma hybrid line [7]. 
The antibody is specific for the protein moiety of 
IFN-fi and completely neutralizes the antiviral activity 
of IFN-fl in a plaque reduction assay on FS4 fibro- 
blasts at a dilution of 1:30, and partly at a dilution of 
1: 100. For immunofluorescent studies the mono- 
clonal antibody had been purified from ascitic fluid 
of Balb-c mice by a 35% ammonium sulfate and a 
subsequent Sephadex G-200 column step in a Tris- 
glycine-butanol buffer (0.2 M Tris-HCl, 0.5 M gly- 
tine, 0.2% n-butanol (pH 7.6)). 
Staining of liver sections was performed by a 1:50 
dilution of a FITC labelled goat anti-mouse IgG 
Cappel Lab., Cochranville PA) for 30 min after a 
washing procedure with barbital buffer @H 7.2). Fol- 
lowing a final washing with barbital buffer the sec- 
tions were mounted in a solution of 9 parts glycerol 
and 1 part barbital buffer. The same staining proce- 
dure was applied in sections of liver specimen obtained 
prior to onset of HIFN-@ treatment of each of the 
3 patients and in sections of liver biopsies of 5 healthy 
subjects without any clinical or histological features 
of liver disease. Liver sections of patients with chronic 
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Fig.1. Demonstration of HIFN$ in cryostat liver sections by indirect immunofluorescence using a monoclonal anti-IFNQ: (A) X 333; 
(B) x 833 
active hepatitis B who were not treated with HIFN-/I 
did not appear to be appropriate controls, since small 
amounts of autologous interferon may be detected 
in some livers of such subjects by indirect immuno- 
fluorescence using the monoclonal mouse anti-HIFN-fl 
applied. Moreover. replicate slides of all livers were 
also stained with normal human immunoglobulin. 
Examination of all sections was performed by the fol- 
lowing optical equipment: fluorescence microscope 
Leitz Ortholux 2, super pressure mercury lamp HBO 
200 W, Ploemopak 2.2 fluorescence incident light 
illuminator, filter block: excitation filter I 2 BP 
450-490 nm, dichroic filter RKP 5 10 nm, barrier fil- 
ter LP 5 15 nm, objectives NPL Fluotar 1010.30, 
2510.55 and 4010.70. 
3. Results and discussion 
A small fringe of bright fluorescence attached to 
the membranes of hepatocytes confining the walls of 
sinusoids were observed throughout the liver lobules 
in the sections of the 3 patients after HIFN-/I treat- 
ment, but were not found in liver sections of the 
same subjects prior to onset of interferon treatment. 
In addition all sections of the 5 individuals with nor- 
mal livers and those of all patients investigated and 
stained with normal immunoglobin were found to be 
completely negative. These data suggest hat HIFNQ 
does indeed reach the liver, and can easily be demon- 
strated by means of indirect fluorescence when given 
intravenously in the above dose. 
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